CheckMate 143, an open-label, randomized, phase III trial, examined the efficacy of nivolumab (anti-PD-1) against bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody approved by the FDA in 2009 for recurrent GBM [32,45]. Here, PDCD1 is linked to glioblastoma.